Cerebrospinal fluid proteome shows disrupted neuronal development in multiple sclerosis.

Area of Science:

• Neuroscience
• Proteomics
• Immunology

Background:

• The etiology of multiple sclerosis (MS) remains unknown, hindering effective treatment strategies.
• Cerebrospinal fluid (CSF) proteomics offers insights into MS pathogenesis but requires accounting for disease heterogeneity.
• Previous analyses identified distinct patient groups based on inflammatory and neural development protein levels.

Purpose of the Study:

• To reanalyze existing CSF proteomics data from MS patients and controls.
• To investigate proteomics data from an independent cohort of clinically isolated syndrome (CIS) patients.
• To identify a common protein signature associated with MS and CIS, independent of intrathecal inflammation.

Main Methods:

• Hierarchical clustering of CSF proteomics data from MS patients and controls.
• Reanalysis of previously reported data and an independent cohort of CIS patients.
• Identification of a common protein signature in MS/CIS patients.

Main Results:

• A common protein signature for MS/CIS was identified, unrelated to elevated intrathecal inflammation.
• This signature is characterized by decreased levels of proteins involved in neural development, including complement proteins, semaphorin-7A, reelin, and neural cell adhesion molecules.
• Low levels of these proteins suggest impaired oxidative capacity and disrupted neural development in early MS/CIS.

Conclusions:

• The identified protein signature provides a novel biomarker for early MS/CIS.
• Disrupted neural development due to low oxidative capacity may be a key factor in MS/CIS pathogenesis.
• Further research into oxidative capacity and neural development pathways is warranted for therapeutic interventions.